Altach Biomedical develops biomimetic cartilage grafts utilizing Type II collagen to create scaffolds that facilitate the regeneration of cartilage defects. This technology addresses the high incidence of untreated cartilage defects, which can lead to osteoarthritis and often result in unsatisfactory long-term outcomes with current repair solutions.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cartilage defects, if left untreated, can lead to osteoarthritis, a condition affecting a significant portion of the adult population. Current cartilage repair solutions often yield unsatisfactory long-term outcomes, result in low-quality cartilage repair, necessitate multiple procedures, or are prohibitively expensive.
Solution
Altach Biomedical is developing a portfolio of biomimetic cartilage scaffolds utilizing Type II collagen, the building block of native cartilage, to address cartilage defects. These scaffolds are designed for standalone use or in conjunction with cell-based therapies. The implants' unique composition creates a matrix that facilitates the migration of the patient's own cells, promoting cartilage regeneration and restoring the patient's quality of life.
Target Audience
The primary target audience includes orthopedic surgeons specializing in sports medicine and joint preservation, as well as hospitals and clinics offering cartilage repair procedures.
Features
- Biomimetic design mimicking the structure and function of native cartilage.
- Type II collagen scaffold promoting cellular integration and cartilage regeneration.
- Compatibility with cell-based therapies for enhanced repair.
- Designed for standalone use, providing versatility in surgical applications.